Tuning the cytotoxic properties of new ruthenium(III) and ruthenium(II) complexes with a modified bis(arylimino)pyridine Schiff base ligand using bidentate pyridine-based ligands
- 571 Downloads
Synthesis, spectroscopy, characterization, structures, and cytotoxicity studies of 2,6-bis(2,6-diisopropylphenyliminomethyl)pyridine (LLL) ruthenium compounds are described. The starting compound [RuCl3(LLL)] has been fully characterized using IR spectroscopy, UV–vis spectroscopy, electrospray ionization mass spectrometry, and NMR spectroscopy. In addition, the crystal structure of the ligand LLL has been determined using single-crystal X-ray diffraction. With the ruthenium(III) trichloride compound as starting material, a new family of Ru(II) complexes with a number of neutral and charged bidentate co-ligands have been synthesized and used for characterization and cytotoxicity studies. The synthesis of the corresponding [RuIILLL(LL)Cl]+/0 complexes with co-ligands— LL is 1,10-phenanthroline, 2,2′-bipyridyl, 2-(phenylazo)pyridine, 2-(phenylazo)-3-methylpyridine, 2-(tolylazo)pyridine, or the anionic 2-picolinate—is reported. Analytical, spectroscopic (IR spectroscopy, UV–vis spectroscopy, 1H NMR spectroscopy, and electrospray ionization mass spectrometry), and structural characterization of the new compounds is described. Crystal structure analyses of two Ru(II) compounds show a slightly distorted octahedral Ru(II) geometry with tridentate LLL coordinated in a planar meridional fashion, and the chelating co-ligand (LL) and a chloride ion complete the octahedron. The co-ligand plays a significant role in modulating the physicochemical and cytotoxic properties of these new ruthenium complexes. The in vitro cytotoxicity of these new Ru(II) complexes (half-maximal inhibitory concentration, IC50, of 0.5–1.5 μM), in comparison with the parent Ru(III) compound (half-maximal inhibitory concentration of 3.9–4.3 μM) is higher for several of the human cancer cell lines tested. The cytotoxic activity of some of the new ruthenium compounds is even higher than that of cisplatin in the same cancer cell lines. The cytotoxicity of these new anticancer compounds is discussed in the light of structure-based activity relationships, and a possible mechanism of action is suggested.
Synthesis, spectroscopy, structures, and cytotoxicity studies of new Ru(III) and Ru(II) compounds with a substituted bis(arylimino)pyridine ligand and bidentate co-ligands are reported. The co-ligands play a significant role in modulating the physicochemical and cytotoxic properties. The in vitro cytotoxicity data are discussed in the light of structure-based activity relationships (SARs).
The synthesis, structure, and spectroscopic characterization of 2,6-bis(2,6-diisopropylphenyliminomethyl)pyridine, a tridentate Schiff base ligand, are reported.
A new Ru(III) complex with a bis(arylimino)pyridine Schiff base ligand has been synthesized and characterized spectroscopically.
A family of Ru(II) compounds with a bis(arylimino)pyridine Schiff base ligand as a primary ligand and bidentate pyridine-based co-ligands are reported.
The cytotoxic activity of Ru(II) and Ru(III) compounds has been studied systematically.
KeywordsRuthenium Bis(arylimino)pyridine derivatives 2,6-Bis(2,6-diisopropylphenyliminomethyl)pyridine Co-ligand Cytotoxic properties
Half-maximal inhibitory concentration
Nuclear magnetic resonance
The authors thank Johnson Matthey (Reading, UK) for the generous loan of RuCl3·3H2O. This work was supported in part (A.G.-O., J.R., M.A.S., M.L.) by the Council for the Chemical Sciences of the Netherlands Organization for Scientific Research (CW-NWO) and in part by CONACYT (National Council of Science and Technology) as a doctoral fellowship to A.G.-O. We thank A.W.M. Lefeber for assistance with the NMR experiments, and Jos van Brussel, John A.P.P. van Dijk, and Jopie A. Erkelens-Duijndam for technical assistance with the syntheses and analyses. The in vitro cytotoxicity experiments were performed by P.F. van Cuijk in the Laboratory of Translational Pharmacology, Department of Medical Oncology. Erasmus Medical Center, Rotterdam, The Netherlands, under the supervision of E.A.C. Wiemer and G. Stoter. A.G.-O. expresses gratitude to the Universidad Autónoma Metropolitana-Xochimilco for a postdoctoral fellowship.
- 8.Greguric A, Greguric ID, Hambley TW, Aldrich-Wright JR, Collins JG (2002) J Chem Soc Dalton Trans 849–855Google Scholar
- 21.Campbell N, Henderson AW, Taylor D (1953) J Chem Soc, 1281–1285Google Scholar
- 30.Beurskens PT, Beurskens G, de Gelder R, Garcia-Granda S, Gould RO, Israel R, Smits JMM (1999) The DIRDIF99 program system, technical report of the Crystallography Laboratory. University of NijmegenGoogle Scholar
- 32.Sheldrick GM (1999–2003) SADABS. University of GöttingenGoogle Scholar
- 34.Boyd MR (1989) In: NCI (ed) Principles and practice of oncology, vol 3. pp 1–12Google Scholar
- 35.Garza-Ortiz A, Maheswari PU, Siegler M, Spek AL, Reedijk J (2013) New J ChemGoogle Scholar
- 43.Mondal B, Chakraborty S, Munshi P, Walawalkar MG, Lahiri GK (2000) J Chem Soc Dalton Trans 2327–2335Google Scholar
- 44.Yang XJ, Drepper F, Wu B, Sun WH, Haehnel W, Janiak C (2005) Dalton Trans 256–267Google Scholar
- 45.Seddon EA, Seddon KR (1984) The chemistry of ruthenium. Elsevier, AmsterdamGoogle Scholar
- 46.van der Schilden K (2006) PhD thesis, Leiden UniversityGoogle Scholar
- 47.Velders AH, van der Geest B, Kooijman H, Spek AL, Haasnoot JG, Reedijk J (2001) Eur J Inorg Chem 2001:369–372Google Scholar
- 49.Mondal B, Walawalkar MG, Lahiri GK (2000) J Chem Soc Dalton Trans 4209–4217Google Scholar
- 51.Hotze ACG (2003) PhD thesis, Leiden UniversityGoogle Scholar
- 52.Garza-Ortiz A (2008) PhD thesis, Leiden UniversityGoogle Scholar
- 53.Hotze ACG, van der Geer EPL, Kooijman H, Spek AL, Haasnoot JG, Reedijk J (2005) Eur J Inorg Chem 2005:2648–2657Google Scholar